The failures of two bought-in assets leave a third hopelessly exposed to the Covid-19 lockdown.
Using drugs that can cause or exacerbate lung infections to treat the novel coronavirus – what could go wrong?
The fragile X pipeline is strewn with failures, and crunch time is approaching for Zynerba’s cannabinoid.
Clinical results this year from companies including Roche, Biogen and Sanofi should show whether new drug classes can arrest the development of Parkinson’s disease.
The US regulator granted 14 accelerated approvals in 2019, fewer than in the previous two years, and the sector remains slow at conversions.
Four assets with previous rejections are due FDA decisions in February, while those with priority review could become the next string of early approvals.
Megadeals flattered the biopharma M&A scene in the first half of 2019, but the numbers took a nose dive in the third-quarter.
Lundbeck needed a deal, but it could struggle against strong competition in migraine.
By taking out Abide Therapeutics, Lundbeck has bought one of very few clinical-stage Tourette’s syndrome candidates.